China-Biotics and Sinovac Biotech Benefit From China's Biotech Revolution
May 27 2011 - 7:16AM
Marketwired
With an improving quality of life that has resulted in larger
paychecks and a more sophisticated understanding of health and
wellness, China has been experiencing a massive biotech boom in
recent years. The Bedford Report examines the outlook for companies
in China's Healthcare Sector and provides research reports on
China-Biotics, Inc. (NASDAQ: CHBT) and Sinovac Biotech Ltd.
(NASDAQ: SVA). Access to the full company reports can be found at:
www.bedfordreport.com/2011-05-CBHT
www.bedfordreport.com/2011-05-SVA
China's economic minister recently tapped biotech as one of
seven key industries that the government intends to foster over the
next 10 years. Zhou Zixue, chief economist of the Ministry of
Industry and Information Technology, projects that biotech in China
will grow at an annual rate of 24.1 percent between 2011 and 2015
before slowing down to a 21.3 percent growth rate in the following
five years.
Sources told Reuters that in order to reach the goal China is
considering investments of up to $1.5 trillion over the next five
years in the industries of next-generation information technology,
energy-saving, biotechnology and high-end equipment
manufacturing.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
Sinovac is a China-based biopharmaceutical company that focuses
on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases including
hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza
and H1N1 influenza. Sinovac reported a net loss of $2.1 million, or
5 cents per share, in the three months ended March 31 versus a net
loss of $300,000, or a penny per share, a year ago.
China-Biotics engages in the research, development, marketing
and distribution of probiotics dietary supplements in China. Jinan
Song, CEO and Chairman of China-Biotics, explains that while the
company is focused on improving market share domestically, the
company looks forward to "future growth opportunities in the
international market." In March the company announced that it
received a product sales order from a newly signed US customer --
its first order from the US.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
China-Biotics, Inc. (MM) (NASDAQ:CHBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
China-Biotics, Inc. (MM) (NASDAQ:CHBT)
Historical Stock Chart
From Oct 2023 to Oct 2024